NCT04537377进行中（未招募）1 期
A Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design, 5-year Follow-up, Single Dose-escalation Study of VTX-801 in Adult Patients With Wilson's Disease
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 4
- 试验地点
- 10
- 主要终点
- Safety and Tolerability Profile (Including Treatment-emergent Adverse Events (TEAE)) - Number of Participants
研究概览
简要总结
The objectives of this clinical trial are to assess, for up to 5 years, the safety, tolerability and pharmacological activity of a single ascending doses of VTX-801, a gene therapy, administered intravenously (IV) to adult patients with Wilson's Disease prior to and following background WD therapy withdrawal.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Main Inclusion Criteria:
- •Male or female aged 18 and 65 years inclusive
- •Confirmed diagnosis of WD
- •Treated for WD according to international recommendations with no current evidence for inadequate treatment
- •Stable WD for ≥ 1 year, defined as: (i) No significant change in neurologic examination and in status of mood disorder and (ii) Stable laboratory parameters used to assess copper metabolism
排除标准
- •ALT level ≥ 2 ULN that is not readily explained by extrinsic factors
- •Total bilirubin > 1.5 x ULN in the absence of proven Gilbert's syndrome; in case of Gilbert's syndrome, direct bilirubin > ULN
- •INR > 1.2
- •Any signs of liver cirrhosis decompensation, including gastrointestinal bleed within 6 months (24 weeks) prior to screening/enrollment visit
- •Patient has moderate or severe renal impairment defined as eGFR CKD-EPI < 60 mL/min/1.73 m2, or patient has nephritis or nephrotic syndrome
- •Any history or current evidence of HIV-1, HIV-2, HTLV 1, or HTLV-2 infection
- •Any history or current evidence of hepatitis B infection
- •Any history of hepatitis C infection, unless previous viral RNA assays in two samples, collected at least 6 months apart, are negative
- •Positive QuantiFERON®-TB Gold tuberculosis test result
- •Any concomitant disorder/condition - including hepatic disorders - or treatment possibly interfering with the conduct or evaluation of the study
- •Any history of diabetes
- •Pregnancy or breastfeeding
- •Body Mass Index ≥ 35 kg/m2
- •Other protocol defined Inclusion/ Exclusion criteria may apply
研究组 & 干预措施
VTX-801
Experimental
干预措施: VTX-801 (Genetic)
结局指标
主要结局
Safety and Tolerability Profile (Including Treatment-emergent Adverse Events (TEAE)) - Number of Participants
时间窗: through primary completion visit, an average of 1 year
AEs will be summarized based on the date of onset for the event. Number of treatment-emergent AEs will be provided by SOC and PT, by dose cohort and overall.
次要结局
- Free Serum Cu(through primary completion visit, an average of 1 year)
- Total Serum Cu(through primary completion visit, an average of 1 year)
- 24-hour Urinary Cu(through primary completion visit, an average of 1 year)
- Serum Ceruloplasmin Activity (Enzymatic Assay)(through primary completion visit, an average of 1 year)
- VTX-801 Responder Status(At Week 12 and Week 36)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
2 期
PRO 140 in Treatment-Experienced HIV-1 SubjectsHIV-1-infectionNCT03902522CytoDyn, Inc.6
招募中
1 期
A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid TumorsMalignant Solid TumorsNCT06737731Suzhou Suncadia Biopharmaceuticals Co., Ltd.300
尚未招募
1 期
BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT05715398Shanghai Gopherwood Biotech Co., Ltd.90
招募中
1 期
Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND1 MutationsLeber Hereditary Optic Neuropathy (LHON)NCT05820152Neurophth Therapeutics Inc18
已完成
2 期
An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid ArthritisRheumatoid ArthritisNCT02049138AbbVie493